Literature DB >> 26043152

Transfemoral aortic valve implantation with the repositionable Lotus valve compared with the balloon-expandable Edwards Sapien 3 valve.

Jochen Wöhrle1, Birgid Gonska2, Christoph Rodewald2, Ulrike Trepte2, Sabrina Koch2, Dominik Scharnbeck2, Julia Seeger2, Sinisa Markovic2, Wolfgang Rottbauer2.   

Abstract

BACKGROUND: The rate of paravalvular aortic insufficiency (AI) with transcatheter aortic valve implantation (TAVI) with first generation devices was higher compared with surgical replacement. Residual AI after TAVI has been linked to an increased mortality rate. We compared two second generation TAVI devices - the repositionable Lotus valve with the balloon-expandable Edwards Sapien 3 valve - regarding procedural and 30 day outcome. METHODS AND
RESULTS: In 78 patients with severe aortic stenosis undergoing transfemoral TAVI we evaluated post-procedural paravalvular AI, device success and early safety according to VARC criteria. Valve size was based on a 256-multislice computed tomography. Patients were followed for 30 days. The Lotus valve (N = 26) and the Edwards Sapien 3 valve (N = 52) were implanted under fluoroscopic guidance. Baseline characteristics were similar between groups. Perimeter derived annulus diameter did not differ with 25.7 ± 1.6mm for Lotus and 25.2 ± 2.1mm for Edwards Sapien 3 patients. After TAVI aortography and transthoracic echocardiography revealed no moderate or severe AI. The rate of mild AI was 12% for Lotus and 15% for Edwards Sapien 3 (p = 0.62). There were no deaths, stroke, annulus rupture or coronary obstruction. Device success was 96% and 98% (p = 0.61), early safety according to VARC 11.5% in both groups (p = 1.0) and the need for pacemaker implantation 27% and 4% (p < 0.003), respectively.
CONCLUSIONS: TAVI with second-generation devices was associated with no moderate or severe AI and a low rate of mild AI. Device success was high for Lotus and Edwards Sapien 3 while the need for permanent pacemaker was significantly higher with the Lotus valve.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Aortic stenosis; Edwards Sapien 3; Lotus; Pacemaker; Transcatheter aortic valve implantation

Mesh:

Year:  2015        PMID: 26043152     DOI: 10.1016/j.ijcard.2015.05.139

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  11 in total

1.  Non-contrast-enhanced magnetic resonance angiography is equal to contrast-enhanced multislice computed tomography for correct aortic sizing before transcatheter aortic valve implantation.

Authors:  Peter Bernhardt; Christoph Rodewald; Julia Seeger; Birgid Gonska; Dominik Buckert; Michael Radermacher; Vinzenz Hombach; Wolfgang Rottbauer; Jochen Wöhrle
Journal:  Clin Res Cardiol       Date:  2015-09-22       Impact factor: 5.460

2.  Head to head transcatheter heart valve comparisons: when theory becomes reality.

Authors:  Gabriela Tirado-Conte; German Armijo; Luis Nombela-Franco
Journal:  Cardiovasc Diagn Ther       Date:  2018-08

3.  Predictors for permanent pacemaker implantation in patients undergoing transfemoral aortic valve implantation with the Edwards Sapien 3 valve.

Authors:  Birgid Gonska; Julia Seeger; Mirjam Keßler; Alexander von Keil; Wolfgang Rottbauer; Jochen Wöhrle
Journal:  Clin Res Cardiol       Date:  2017-03-10       Impact factor: 5.460

4.  Patient-specific registration of 3D CT angiography (CTA) with X-ray fluoroscopy for image fusion during transcatheter aortic valve implantation (TAVI) increases performance of the procedure.

Authors:  I Vernikouskaya; W Rottbauer; J Seeger; B Gonska; V Rasche; Jochen Wöhrle
Journal:  Clin Res Cardiol       Date:  2018-02-16       Impact factor: 5.460

5.  Mechanisms of Heart Block after Transcatheter Aortic Valve Replacement - Cardiac Anatomy, Clinical Predictors and Mechanical Factors that Contribute to Permanent Pacemaker Implantation.

Authors:  Mark Young Lee; Srinath Chilakamarri Yeshwant; Sreedivya Chava; Daniel Lawrence Lustgarten
Journal:  Arrhythm Electrophysiol Rev       Date:  2015-08

6.  Transcatheter aortic valve implantation with the new-generation Evolut R™: Comparison with CoreValve® in a single center cohort.

Authors:  Eberhard Schulz; Alexander Jabs; Tommaso Gori; Stephan von Bardeleben; Ulrich Hink; Walter Kasper-König; Christian Friedrich Vahl; Thomas Münzel
Journal:  Int J Cardiol Heart Vasc       Date:  2016-07-05

7.  Transfemoral Aortic Valve Implantation with the New Edwards Sapien 3 Valve for Treatment of Severe Aortic Stenosis-Impact of Valve Size in a Single Center Experience.

Authors:  Jochen Wöhrle; Birgid Gonska; Christoph Rodewald; Julia Seeger; Dominik Scharnbeck; Wolfgang Rottbauer
Journal:  PLoS One       Date:  2016-03-22       Impact factor: 3.240

8.  A granular approach to improve reproducibility of the echocardiographic assessment of paravalvular regurgitation after TAVI.

Authors:  Mohammad Abdelghani; Ben Ren; Ernest Spitzer; Hiroki Tateishi; Hans Jonker; Marcel L Geleijnse; Jan G Tijssen; Robbert J de Winter; Patrick W J C Serruys; Osama I I Soliman
Journal:  Int J Cardiovasc Imaging       Date:  2016-07-27       Impact factor: 2.357

9.  Influence of permanent pacemaker implantation after transcatheter aortic valve implantation with new-generation devices.

Authors:  B Gonska; M Keßler; J Wöhrle; W Rottbauer; J Seeger
Journal:  Neth Heart J       Date:  2018-12       Impact factor: 2.380

10.  Transcatheter aortic valve replacement with Lotus and Sapien 3 prosthetic valves: a systematic review and meta-analysis.

Authors:  Mirosław Gozdek; Jakub Ratajczak; Adam Arndt; Kamil Zieliński; Michał Pasierski; Matteo Matteucci; Dario Fina; Federica Jiritano; Paolo Meani; Giuseppe Maria Raffa; Pietro Giorgio Malvindi; Michele Pilato; Domenico Paparella; Artur Słomka; Uri Landes; Ran Kornowski; Jacek Kubica; Roberto Lorusso; Piotr Suwalski; Mariusz Kowalewski
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.